Glimeto-MV1 Tablets

Composition

• Glimepiride – 1 mg
• Voglibose – 0.2 mg
• Metformin Hydrochloride (Sustained Release) – 500 mg

---

Mechanism of Action

Metformin Hydrochloride (SR) reduces hepatic glucose production, improves insulin sensitivity, and enhances peripheral glucose uptake. The sustained-release formulation provides gradual drug release, ensuring prolonged glycemic control with improved gastrointestinal tolerability.

Glimepiride stimulates insulin secretion from pancreatic beta cells, helping lower blood glucose levels effectively.

Voglibose delays the digestion and absorption of carbohydrates in the intestine by inhibiting alpha-glucosidase enzymes, thereby reducing postprandial glucose spikes.

---

Key Benefits

• Triple-action approach for superior glycemic control
• Reduces postprandial glucose spikes effectively
• Improves insulin secretion and sensitivity
• Helps lower HbA1c levels
• Sustained-release formulation for prolonged action
• Suitable for patients requiring combination therapy

---

Indications

• Type 2 Diabetes Mellitus
• Patients inadequately controlled on dual therapy
• Advanced combination therapy for better glycemic management

---

Dosage & Administration

• To be taken as directed by the physician
• Usually taken with meals
• Tablets should be swallowed whole and not crushed or chewed

---

Precautions

• Risk of hypoglycemia due to sulfonylurea component
• Gastrointestinal discomfort may occur due to Metformin or Voglibose
• Use cautiously in renal or hepatic impairment
• Regular monitoring of blood glucose is recommended
• Avoid excessive alcohol intake

---

Contraindications

• Type 1 Diabetes Mellitus
• Diabetic ketoacidosis
• Severe renal or hepatic impairment
• Known hypersensitivity to any component

---

Storage

• Store in a cool and dry place below 25°C
• Protect from light and moisture
• Keep out of reach of children

---

Packaging

• 10 x 15 Tablets